| Disease | TO DETERMINE THE LIPID-LOWERING EFFECT OF GARLIC POWDER TABLETS IN PATIENTS WITH HYPERCHOLESTEROLEMIA. THIS WAS A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-WEEK, PARALLEL TREATMENT STUDY CARRIED OUT IN 2 OUTPAIENTS LIPID CLINICS. ENTRY
INTO THE STUDY AFTER 8 WEEKS OF DIET STABILIZATION REQUIRED A MEAN LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVEL ON 2 VISITS OF 4.1 MMOL/L (160 MG/DL) OR LOWER AND A TRIGLYCERIDE LEVEL OF 4.0 MMOL/L (350 MG/DL) OR LOWER. THE ACTIVE TREATMENT ARM
RECEIVED TABLE CONTAINING 300 MG OF GARLIC POWDER (KWAI) 3 TIMES PER DAY, GIVEN WITH MEALS (TOTAL, 900 MG/D) THIS IS EQUIVALENT TO APPROXIMATELY 2.7 G OR APPROXIMATELY 1 CLOVE OF FRESH GARLIC PER DAY. THE PLACEBO ARM RECEIVED AN IDENTICAL-LOOK
ING TABLET, ALSO GIVEN 3 TIMES PER DAY WITH MEALS. THE MAIN OUTCOME MEASURES INCLUDED LEVELS OF TOTAL CHOLESTEROL, TRIGLYCERIDES, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AFTER 12 WEEKS OF TREATMENT. TWENTY-
EIGHT PATIENTS (43% MALE; MEAN + SD AGE, 58 +14 YEARS) RECEIVED GARLIC POWDER TREATMENT AND 22 (68% MALE; MEAN + SD AGE, 57 + 13 YEARS) RECEIVED PLACEBO TREATMENT. THERE WERE NO SIGNIFICANT LIPID OR LIPOPROTEIN CHANGES IN EITHER THE PLACEBO- OR
GARLIC-TREATED GROUPS AND NO SIGNIFICANT DIFFERENCE BETWEEN CHANGES IN THE PALCEBO-TREATED GROUP COMPARED WITH CHANGES IN THE GARLIC-TREATED PATIENTS.
A COMMERCIAL PRODUCT, KWAI, WAS USED. |